Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the prevalence of breakthrough cancer pain and characterize breakthrough cancer pain in an unselected, representative cohort of cancer outpatients with or without pain who attend consultations.


Clinical Trial Description

This study has been designed as a non-interventional, non post-authorization, cross-sectional, epidemiological study to determine the prevalence of breakthrough cancer pain and characterize breakthrough cancer pain in an non-selected, representative cohort of cancer outpatients with or without pain.

The study enrolled 3765 patients. This multicenter trial will be conducted in Spain. Data from participants will be collected through questionnaire and medical history in a single visit (up to 1 month). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02899884
Study type Observational
Source Takeda
Contact
Status Completed
Phase
Start date November 14, 2016
Completion date July 16, 2018

See also
  Status Clinical Trial Phase
Completed NCT01946555 - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain N/A
Recruiting NCT01693328 - Patient Satisfaction and Quality of Life Impact - PecFent® N/A
Recruiting NCT01698645 - Patient Satisfaction and Quality of Life Impact - PecFent® N/A
Completed NCT01936636 - Observational Registry Study of Quality of Life When Treating BTcP With Abstral N/A
Completed NCT05531422 - Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP Phase 2
Completed NCT03669263 - A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan N/A
Recruiting NCT03564548 - Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain Phase 2
Not yet recruiting NCT04713189 - Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain Phase 1/Phase 2
Completed NCT03895762 - Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
Terminated NCT01439919 - A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain Phase 2
Completed NCT01045603 - Instanyl® Non-Interventional Study N/A
Recruiting NCT00822614 - Safety of Fentanyl TAIFUN Treatment Phase 3
Terminated NCT04468490 - Treatment of Breakthrough Cancer Pain According to European Guidelines